comparemela.com

Latest Breaking News On - வணிகமயமாக்கல் மையம் - Page 5 : comparemela.com

Research agenda as a catalyst to propel Universiti Teknologi Malaysia s (UTM) vision and mission

February 05, 2021 Making an impact in the community JOHOR BAHRU, Malaysia, Feb. 5, 2021 /PRNewswire/ UTM has established a consortium known as AIMS4STAR which stands for Academia, Industry, Government and Society for Synergistic Transformation. It is a strategic platform to solve problems in the community, industry and, the country made possible by collaborating with community and industry partners. It functions as a quadruple helix strength that can converge and market UTM expertise in providing innovative solutions for industry and society towards SUSTAINABLE IMPACT. AMTEC staff installing a mobile water treatment system at SK Pos Poi, Sungai Siput. UTM Recognizes Industry Partners Contributions

UTM-AU to Design Best Practices of R&D Commercialization for Malaysia and UK Universities

JOHOR BAHRU – A Memorandum of Understanding (MoU) was signed between Universiti Teknologi Malaysia (UTM) and University of Aberystwyth (AU) and Aberystwyth Innovation and Enterprise Campus (AberInnovation) from United Kingdom (UK) on 16 December 2020. The online signing ceremony took place in the Main Meeting Room (BMU) of UTM Johor Bahru campus with Prof. Datuk Ts. Dr. Ahmad Fauzi Ismail who is the acting Vice-Chancellor of UTM signing on behalf of the university. Meanwhile, the co-signatory parties were the Vice-Chancellor of Aberystwyth University, Prof. Dr. Elizabeth Treasure and Chief Executive Officer (CEO) of AberInnovation and Enterprise Campus, Dr. Rhian Hayward. Prof. Fauzi in his speech highlighted the aspects of commercialisation which is the importance of drawing an effective strategy as a catalyst for technological commercialisation excellence especially in a prosperous innovation ecosystem with many experts, intellectual property, financial assistance, and conduci

ONL Therapeutics Raises $46 9M in Series B Financing

ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round. The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University’s Biosciences Research & Commercialization Center, and the Capital Community Angels.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.